PTPN11 and hematologic disorder: Recently, an oncogenic role for SHP2, which is hyperactivated due to amplification or hyperphosphorylation of SHP2-recruiting/activating proteins, has been reported during oncogenesis in many cancers, especially hematological malignancies (Zhang et al., 2015; Pandey et al., 2017).